Obesity drugs won’t be covered by Medicare under 2026 CMS policy
Snippet of Article: "...The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal to expand Medicare coverage for anti-obesity drugs such as Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide). ...This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion. "
Source: finance.yahoo.com